Exelixis Inc
XMUN:EX9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
E
|
Exelixis Inc
XMUN:EX9
|
US |
|
C
|
CapitaLand Integrated Commercial Trust
XMUN:M3T
|
SG |
|
Danske Bank A/S
OTC:DNSKF
|
DK |
|
P
|
Paychex Inc
XETRA:PCX
|
US |
|
B
|
Bear Creek Mining Corp
OTC:BCEKF
|
CA |
|
O
|
Outcrop Silver & Gold Corp
XBER:MRG
|
CA |
Exelixis Inc
Exelixis is a biotechnology company that develops and sells prescription cancer medicines. Its core business is discovering drug candidates, running clinical trials, getting them approved, and then marketing them through pharmaceutical sales channels. The company is best known for oncology treatments used by patients with certain cancers, often as part of long-term therapy plans set by oncologists. The company makes money mainly by selling its approved drugs, usually through wholesalers, specialty pharmacies, and healthcare providers. It also earns revenue from partnerships around drug development and commercialization, such as licensing arrangements, milestone payments, and royalties when partners help bring a medicine to market or sell it in other territories. What makes Exelixis different is that it is focused on a small number of cancer drug programs rather than a broad drug portfolio. That gives it a business model tied closely to the success of a few key therapies and the medical evidence behind them. In the biotech value chain, Exelixis sits between early-stage drug discovery and full-scale pharmaceutical commercialization, turning lab research into marketed cancer treatments.
Exelixis is a biotechnology company that develops and sells prescription cancer medicines. Its core business is discovering drug candidates, running clinical trials, getting them approved, and then marketing them through pharmaceutical sales channels. The company is best known for oncology treatments used by patients with certain cancers, often as part of long-term therapy plans set by oncologists.
The company makes money mainly by selling its approved drugs, usually through wholesalers, specialty pharmacies, and healthcare providers. It also earns revenue from partnerships around drug development and commercialization, such as licensing arrangements, milestone payments, and royalties when partners help bring a medicine to market or sell it in other territories.
What makes Exelixis different is that it is focused on a small number of cancer drug programs rather than a broad drug portfolio. That gives it a business model tied closely to the success of a few key therapies and the medical evidence behind them. In the biotech value chain, Exelixis sits between early-stage drug discovery and full-scale pharmaceutical commercialization, turning lab research into marketed cancer treatments.
Revenue: Exelixis reported first-quarter 2026 total revenue of approximately $611 million, driven by CABOMETYX net product revenue of $552.8 million and $45.9 million in royalties.
Growth: The cabo franchise kept gaining momentum, with U.S. cabo franchise net product revenue up 8% year over year and global cabo franchise revenue up 12.5% to $764 million.
Launch prep: Management said zanzalintinib is the company’s top priority, with the CRC NDA under review and a PDUFA date in early December; launch planning is already in full swing.
Pipeline breadth: Exelixis expanded zanza development with multiple new studies, including STELLAR-201 in meningioma and planned trials in squamous NSCLC and metastatic prostate cancer.
Capital return: The company bought back about $430.8 million of stock in the quarter, completed most of the prior authorization, and added a new $750 million repurchase plan.
Outlook: Management reiterated full-year 2026 financial guidance and said 2026 could be a potentially transformational year for the company.
